RNS Number : 5191E
Eco Animal Health Group PLC
27 February 2024
 


ECO Animal Health Group plc

("ECO" or the "Company")

 

Publication of Notice of General Meeting

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it is today publishing a notice of general meeting (the "Notice") to be held on 19 March 2024 to seek shareholders' approval for the board to make limited on market purchases of the Company's ordinary shares of 5 pence each ("Ordinary Shares").

 

On 8 January 2024, the Company announced the disposal of certain freehold properties and the board stated that it intends to use the majority of the proceeds to advance the growth aspirations of ECO. Assuming the necessary resolution is passed, the Board also intends to use some of the proceeds to purchase Ordinary Shares in the market to cover possible future vesting of employee share-based incentives including share options, long term incentive plans and the deferred bonus scheme.

 

The Notice will be available shortly on the Company's website at www.ecoanimalhealth.com.

 

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)


020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

 

  


 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGUNVWRSBUUUAR
Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Eco Animal Health.
Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Eco Animal Health.